查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1931286

磷酰二胺吗啉代寡聚物市场按应用、给药方式、最终用户、配方和分销管道划分，全球预测，2026-2032年

Phosphorodiamidate Morpholino Oligomers Market by Application, Delivery Modality, End User, Formulation, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年磷酰二胺酸吗啉代寡聚物市场价值为 1.8322 亿美元，预计到 2026 年将成长至 2.0721 亿美元，预计到 2032 年将达到 4.637 亿美元，复合年增长率为 14.18%。

关键市场统计数据
基准年 2025 1.8322亿美元
预计年份：2026年 2.0721亿美元
预测年份 2032 4.637亿美元
复合年增长率 (%) 14.18%

磷酰二胺酸吗啉寡聚物（PMO）的全面介绍：重点阐述其化学优势、临床应用和策略发展考量

磷酰二胺吗啉代寡聚物（PMO）是一类独特的反义寡核酸分子，已从实验室研究发展成为检验的治疗方法。其特异性的骨架化学结构赋予其对核酸酶的抗性，并减少脱靶效应，从而能够靶向调控RNA剪接和基因表现。在临床上，PMO已在遗传疾病的外显子跳跃治疗策略中展现出效用，随着化学、偶联技术和递送系统的进步，目前正在感染疾病和肿瘤治疗计画中进行评估。

偶联化学、监管政策和製剂策略的进步如何重塑PMO疗法的临床和商业性进程

分子设计、偶联策略、监管先例和递送科学的进步汇聚一堂，正推动药物标靶治疗（PMO）领域发生变革性转变。脂质和胜肽偶联化学的进步提高了药物组织穿透性和目标细胞吸收效率，从根本上改变了治疗方法，拓展了适应症范围，使其超越了传统的神经肌肉疾病。这些递送创新降低了对高剂量全身给药的依赖，并使研发人员能够重新评估敏感组织中安全性和有效性之间的权衡。

评估2025年美国关税累积调整对专案管理办公室（PMO）开发与製造的营运、供应链与策略影响

近期贸易政策的发展，包括2025年生效的累积关税，为全球专案管理办公室（PMO）生态系统带来了新的复杂性。这些关税将影响原料、特殊试剂和某些生产设备，推高生产成本并影响采购决策。开发人员和製造商现在必须重新评估其供应商网络，尽可能优先考虑垂直整合的供应链，并权衡近岸外包和分散式全球采购之间的利弊，以降低关税风险。

基于深度细分的洞察，揭示了应用、给药方式、最终用户需求、配方和分销管道如何共同决定PMO的开发和商业化路径。

透过这种细分，我们得以洞察临床价值、研发复杂性和商业性机会在应用、给药方式、终端用户、製剂和分销管道等方面的交汇点。在所有适应症中，遗传性疾病仍然是核心关注点，其中Duchenne氏肌肉失养症和脊髓性肌肉萎缩症特别受关注。在Duchenne氏肌肉失养症项目中，外显子跳跃策略正推动PMO的临床应用。同时，感染疾病计画正朝着细菌和病毒标靶发展，这反映了不同的给药和动态要求。肿瘤计画则专注于乳癌和肺癌等肿瘤类型，正在研究标靶剪接调控和RNA标靶通路，每种通路都需要客製化的生物分布和安全性特征。

美洲、欧洲、中东和非洲以及亚太地区的临床、监管和生产趋势正在影响专案管理办公室 (PMO) 的发展和存取策略。

区域趋势对临床开发策略、监管互动和製造地选择有着深远的影响。在美洲，成熟的临床试验体系、反义疗法的既定监管先例以及密集的专业生产商和合约服务供应商网络，正在加速转化研究的发展。这种环境既支持首次人体临床试验和迭代式临床设计，也要求严格的安全性和终点论证，以满足支付者和临床医生的需求。

致力于推进专案管理办公室（PMO）技术、整合化学专业知识、生产规模和临床应用能力的组织的策略和营运重点

与专案管理办公室 (PMO) 合作的领先机构的企业策略强调化学、偶联、临床开发和生产方面的整合能力。成功的公司将反义寡核苷酸疗法的深厚科学专长与强大的转化管线以及执行针对罕见疾病和特殊领域的复杂临床项目的能力相结合。策略伙伴关係和授权协议通常能够加速获取专有偶联技术和区域分销网络，使申办方能够将分子设计的优势与成熟的商业化管道相结合。

切实可行的策略建议，旨在协调交付创新、供应链韧性、监管参与和商业性执行，从而有效推进您的 PMO 专案。

产业领导者应采取多管齐下的策略，将科学创新与切实可行的商业执行结合。首先，他们应在药物发现早期阶段优先投资于递送优化，确保偶联形式（脂质、胜肽或非偶联）的选择体现在候选药物筛选、毒理学测试方案和剂量探索策略中。早期协调有助于降低后续开发风险，并明确液体製剂和冷冻干燥製剂的生产要求。

调查方法结合了专家的一手研究、严格的二手检验和资料三角测量，为专案管理办公室 (PMO) 的开发和商业化提供了切实可行的见解。

本分析整合了第一手和第二手调查方法，以确保对PMO（药物市场开发）的开发和商业化动态提供全面而平衡的观点。第一手研究包括对药物化学、临床开发、法规事务和生产製造领域的专家进行结构化访谈，并辅以与寡核苷酸专案经验丰富的供应链和采购负责人进行的私下讨论。这些工作提供了关于偶联物性能、临床运营挑战以及应对关税变化的策略采购措施的定性见解。

对PMO治疗方案成功转化为临床应用所需的科学潜力、营运挑战和策略重点进行综合分析

磷酰二胺吗啉代寡聚物（PMO）在广泛的RNA标靶治疗领域占据着极具吸引力的地位，它们兼具化学稳定性、序列特异性以及在遗传疾病、感染疾病和肿瘤学等领域的潜在临床应用价值。偶联化学和製剂科学的进步显着拓展了PMO的给药途径，从而拓宽了其发挥重要作用的治疗领域。同时，监管政策的日益明确和临床终点的日趋成熟也为更可靠的研发路径奠定了基础。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依应用分類的磷酰二胺吗寡聚物市场

  • 遗传性疾病
    • DMD
    • Sma
  • 感染疾病
    • 细菌感染疾病
    • 病毒感染疾病
  • 肿瘤学
    • 乳癌
    • 肺癌

9. 依递送方式分類的磷酰二胺吗寡聚物市场

  • 脂质结合
    • 胆固醇
    • 多可沙尼尔
  • 肽键类型
    • 穿透胜肽
    • Tat
  • 未绑定类型

10. 依最终用户分類的磷酰二胺吗寡聚物市场

  • 合约研究机构
  • 医院和诊所
  • 製药和生物技术公司
  • 研究所

11. 依配方分類的磷酰二胺吗寡聚物市场

  • 液体
  • 冻干粉

12. 依分销通路分類的磷酰二胺吗寡聚物市场

  • 离线
  • 在线的

13. 磷酰二胺吗啉代寡聚物市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

14. 磷酰二胺吗啉代寡聚物市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国磷酰二胺吗寡聚物市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国磷酰二胺吗啉代寡聚物市场

17. 中国磷酰二胺吗啉代寡聚物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Aurigene Pharmaceutical Services Pvt. Ltd.
  • Aurobindo Pharma Ltd.
  • Avidity Biosciences, Inc.
  • BioMarin Pharmaceutical Inc.
  • Biosynth AG
  • BOC Sciences, Inc.
  • Creative Biogene Corporation
  • Dr. Reddy's Laboratories Ltd.
  • Dyne Therapeutics, Inc.
  • Eurofins Genomics, LLC
  • Gene Link, Inc.
  • Gene Tools, LLC
  • GenElixir, Inc.
  • Inciton, Inc.
  • IntegrateRNA
  • Nippon Shinyaku Co., Ltd.
  • NS Pharma, Inc.
  • Sarepta Therapeutics, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Valence Labs, Inc.
Product Code: MRR-7B550E008E0A

The Phosphorodiamidate Morpholino Oligomers Market was valued at USD 183.22 million in 2025 and is projected to grow to USD 207.21 million in 2026, with a CAGR of 14.18%, reaching USD 463.70 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 183.22 million
Estimated Year [2026] USD 207.21 million
Forecast Year [2032] USD 463.70 million
CAGR (%) 14.18%

Comprehensive introduction to phosphorodiamidate morpholino oligomers highlighting their chemical advantages, clinical translation, and strategic development considerations

Phosphorodiamidate morpholino oligomers (PMOs) represent a distinct class of antisense molecules that have matured from laboratory curiosities into validated therapeutic modalities. Their unique backbone chemistry confers resistance to nucleases and reduces off-target interactions, enabling targeted modulation of RNA splicing and gene expression. Clinically, PMOs have demonstrated utility in exon skipping strategies for genetic disorders and are being evaluated across infectious disease and oncology programs, driven by advances in chemistry, conjugation technologies, and delivery systems.

The current landscape reflects an intersection of scientific rigor and translational momentum. Researchers have refined PMO chemistries and conjugation approaches to enhance cellular uptake while preserving safety profiles. Concurrently, regulatory pathways now accommodate sequence-specific oligonucleotide therapies with precedent-setting approvals that inform review expectations and trial design. As a result, decision-makers in drug development and clinical operations must align discovery-phase optimization with pragmatic delivery strategies and regulatory engagement, since successful translation hinges on integrating molecular design with real-world administration and manufacturing considerations.

This introduction frames the report's emphasis on actionable insight: understanding where PMOs add therapeutic value, how delivery modalities shape clinical viability, and which stakeholder groups-ranging from contract research organizations to hospitals and pharmaceutical developers-will influence adoption. Subsequent sections synthesize scientific, commercial, and policy drivers to inform strategy for R&D prioritization, partnership pursuit, and regional engagement.

How advances in conjugation chemistry, regulatory clarity, and formulation strategies are reshaping the clinical and commercial trajectory of PMO therapeutics

The PMO landscape is undergoing transformative shifts driven by converging advances in molecular design, conjugation strategies, regulatory precedents, and delivery science. Improvements in lipid and peptide conjugation chemistries have materially altered the therapeutic calculus by enabling more efficient tissue penetration and targeted cellular uptake, thereby expanding the scope of indications under investigation beyond classical neuromuscular disorders. These delivery breakthroughs reduce the reliance on high systemic doses and allow developers to re-evaluate safety and efficacy trade-offs in sensitive tissues.

In parallel, clinical programs are evolving from monotherapy proofs-of-concept to combination and adjunctive strategies where PMOs complement gene-replacement or small-molecule approaches. This hybridization reflects a pragmatic recognition that durable clinical benefit may require multimodal interventions tailored to specific genotypes and disease stages. Regulatory clarity for antisense modalities has progressed, creating more predictable development pathways and informing endpoint selection, especially in rare genetic conditions where surrogate and functional outcomes gain prominence.

Commercially, the shift toward specialized manufacturing and formulation flexibility-such as transitioning between liquid and lyophilized presentations-supports broader clinical use and supply chain resilience. Contract research organizations and research institutes are adapting capabilities to support conjugation analytics, long-term toxicology, and advanced pharmacokinetic modeling. Collectively, these shifts are moving PMOs from niche experimental therapies toward integrated platforms that can be systematically optimized for diverse therapeutic areas.

Evaluating the operational, supply chain, and strategic consequences of the cumulative United States tariff adjustments introduced in 2025 for PMO development and manufacturing

Recent trade policy developments, including the implementation of cumulative tariffs in 2025, have introduced a new layer of complexity for the global PMO ecosystem. These tariffs affect raw material inputs, specialized reagents, and certain manufacturing equipment, which in turn exert upward pressure on production costs and influence sourcing decisions. Developers and manufacturers must now reassess supplier networks, prioritize vertically integrated supply chains where feasible, and evaluate the trade-offs between nearshoring versus diversified global sourcing to mitigate tariff exposure.

The tariff environment has practical implications for clinical program planning and procurement cycles. Sponsors negotiating long-term supply agreements with contract manufacturing organizations may face higher baseline costs for repeat runs and stability studies, prompting renegotiation of terms or reconsideration of inventory strategies. Additionally, the burden of increased import duties can accelerate interest in regional manufacturing hubs that reduce cross-border movement of tariff-sensitive goods and shorten logistics timelines, albeit with potential capital expenditure and regulatory compliance trade-offs.

Strategic responses have emerged across the industry spectrum. Some organizations are intensifying supplier qualification efforts to identify tariff-exempt or domestically produced alternatives for key reagents. Others are exploring process optimization and yield improvements to offset cost increases without compromising quality. Finally, stakeholders are engaging more actively with trade advisors and policy experts to track tariff adjustments and identify exemptions or credits that could moderate the cumulative impact. These operational and strategic adaptations will influence where and how PMO programs are manufactured and distributed in the near term.

Deep segmentation-driven insights revealing how application, delivery modality, end-user needs, formulation, and distribution channels jointly determine PMO development and commercialization pathways

Insights derived from segmentation illuminate where clinical value, development complexity, and commercial opportunity intersect across applications, delivery modalities, end users, formulations, and distribution channels. Across application areas, genetic disorders remain a core focus with detailed attention to Duchenne muscular dystrophy and spinal muscular atrophy; within Duchenne programs, exon skipping strategies have catalyzed PMO clinical activity, while infectious disease programs are bifurcated between bacterial and viral targets reflecting distinct delivery and pharmacodynamic requirements. Oncology programs concentrate on tumor types such as breast and lung cancer where targeted splice modulation or RNA-targeted pathways are under exploration, each demanding tailored biodistribution and safety profiles.

Delivery modality segmentation further clarifies technical and clinical priorities. Lipid-conjugated PMOs, including cholesterol and docosanyl derivatives, prioritize membrane interaction and systemic transport, making them attractive for indications requiring broader biodistribution. Peptide-conjugated approaches using moieties like penetratin and Tat focus on receptor-mediated or membrane-penetrating mechanisms to enhance intracellular delivery in hard-to-reach tissues. Unconjugated PMOs, while maintaining favorable safety and metabolic stability, often require higher dosing or optimized administration routes to achieve therapeutic concentrations.

End user segmentation highlights distinct operational needs that shape adoption. Contract research organizations are expanding analytical and scale-up capabilities to support conjugation characterization and GMP production, whereas hospitals and clinics focus on administration protocols, patient monitoring, and real-world safety. Pharmaceuticals and biotech companies drive strategic investment and partnering, aligning clinical portfolios and licensing strategies. Research institutes continue to underpin discovery and mechanism-of-action studies that feed translational pipelines.

Formulation choices between liquid and lyophilized powder influence shelf-life, cold chain logistics, and clinician convenience; each presentation has implications for clinical trial design, storage at point of care, and long-term distribution planning. Distribution channels from direct sales to distributors and online platforms determine how stakeholders access products, with direct sales supporting bespoke commercial relationships and online channels increasingly enabling research-use procurement and faster experimental deployment. Synthesizing these segmentation layers helps stakeholders prioritize development pathways, tailor delivery systems to indication-specific needs, and align commercial models with end-user capabilities.

Regional clinical, regulatory, and manufacturing dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape PMO development and access strategies

Regional dynamics exert a powerful influence on clinical development strategies, regulatory engagement, and manufacturing footprint decisions. In the Americas, a mature clinical trial ecosystem, well-established regulatory precedents for antisense therapies, and a dense network of specialized manufacturers and contract service providers accelerate translational momentum. This environment supports first-in-human studies and iterative clinical designs but also demands rigorous safety and endpoint justification to satisfy payers and clinicians.

Europe, the Middle East, and Africa present a heterogeneous landscape where regulatory frameworks, reimbursement models, and clinical infrastructure vary significantly. European regulatory bodies have demonstrated adaptability in evaluating sequence-specific therapeutics, and collaborations across academic centers support multinational trials. Meanwhile, capacity constraints in certain regions within EMEA create opportunities for partnerships with regional CROs and for establishing local manufacturing capacities to improve access and reduce logistical barriers.

Asia-Pacific combines rapid investment in biopharmaceutical R&D with expanding manufacturing capabilities and growing clinical trial participation. Several countries in the region are strengthening regulatory pathways for innovative modalities and investing in biotech clusters that support scale-up and commercialization. For PMO developers, APAC offers access to diverse patient populations for clinical studies and potential manufacturing efficiencies, but stakeholders must calibrate regulatory strategies to meet country-specific requirements and ensure quality alignment across multinational supply chains.

Understanding these regional differences enables sponsors to sequence clinical development, prioritize regulatory engagements, and design supply chain architectures that balance speed, cost, and compliance across the Americas, EMEA, and Asia-Pacific.

Corporate strategies and operational priorities among organizations advancing PMO technologies that combine chemistry expertise, manufacturing scale, and clinical translational capabilities

Corporate strategies among leading organizations working with PMOs emphasize integrated capabilities in chemistry, conjugation, clinical development, and manufacturing. Successful players combine deep scientific expertise in antisense modalities with robust translational pipelines and an ability to execute complex clinical programs for rare and specialty indications. Strategic partnerships and licensing arrangements often accelerate access to proprietary conjugation technologies or regional distribution networks, enabling sponsors to pair molecular design strengths with established commercialization channels.

Investment in manufacturing and analytical platforms is a common theme among incumbent and emerging companies. Firms that prioritize scalable GMP processes, advanced impurity profiling, and stability science create practical advantages when transitioning from early-phase trials to broader clinical deployment. In addition, commercialization-minded organizations are developing differentiated formulations, such as heat-stable lyophilized products or clinically convenient liquid preparations, to reduce barriers at the point of care and to support diverse administration settings.

Competitive positioning also reflects variation in therapeutic focus. Some companies concentrate on exon skipping and neuromuscular disorders with deep clinical expertise and patient advocacy engagement, while others target infectious disease or oncology applications that require distinct delivery paradigms and translational evidence. Across the ecosystem, firms that integrate patient-centric trial design, robust regulatory engagement, and partnerships with specialized contract research and manufacturing providers are best positioned to advance PMO candidates from discovery to clinical utility.

Actionable strategic recommendations to align delivery innovation, supply chain resilience, regulatory engagement, and commercial execution for advancing PMO programs efficiently

Industry leaders should adopt a multifaceted strategy that aligns scientific innovation with pragmatic operational execution. First, prioritize investment in delivery optimization early in the discovery phase so that conjugation choices-whether lipid, peptide, or unconjugated formats-inform candidate selection, toxicology planning, and dose-ranging strategies. Early alignment reduces downstream development risk and clarifies manufacturing requirements for both liquid and lyophilized formulations.

Second, strengthen supply chain resilience by diversifying suppliers for critical reagents, qualifying regional manufacturers, and exploring nearshoring options where tariff and logistical pressures are material. Engaging with contract research and manufacturing partners to build redundancy and to document robust quality systems will mitigate exposure to trade policy shocks and accelerate clinical supply availability. Third, cultivate regulatory and payer dialogues early to define acceptable clinical endpoints, safety expectations, and evidence packages, particularly for rare genetic disorders where surrogate outcomes and real-world evidence may support regulatory and reimbursement pathways.

Fourth, pursue pragmatic commercial models that tailor distribution approaches to end-user needs: direct engagement for complex clinical programs and partnerships with distributors or online channels for research and smaller-scale clinical deployments. Finally, invest in cross-functional capabilities that bridge discovery, CMC, clinical operations, and commercialization to ensure a cohesive development plan. These actions together reduce technical and commercial risk and increase the likelihood that PMO programs will achieve both clinical and market adoption objectives.

Methodological approach combining expert primary research, rigorous secondary validation, and data triangulation to deliver actionable insights into PMO development and commercialization

This analysis synthesizes primary and secondary research methods to ensure a robust and balanced perspective on PMO development and commercialization dynamics. Primary inputs included structured interviews with subject-matter experts across medicinal chemistry, clinical development, regulatory affairs, and manufacturing, supplemented by confidential discussions with supply chain and procurement leaders experienced in oligonucleotide programs. These engagements provided qualitative insights into conjugation performance, clinical operations challenges, and strategic sourcing responses to tariff changes.

Secondary research drew on peer-reviewed literature, regulatory guidance documents, company disclosures, and technical white papers to validate mechanistic and clinical observations. The methodology applied data triangulation to reconcile differing viewpoints and to corroborate technical claims with published evidence. Analytical techniques incorporated thematic synthesis, risk-impact mapping, and scenario analysis to translate technical detail into strategic implications for stakeholders at different points along the value chain.

Where uncertainties persisted, expert consensus was used to frame risk areas and mitigation strategies, and sensitivity to regional regulatory differences was embedded throughout the analysis. The result is a methodology-oriented narrative that balances empirical evidence with practitioner insights, offering decision-relevant conclusions while acknowledging ongoing scientific and policy developments.

Concluding synthesis of scientific promise, operational challenges, and strategic priorities that determine the translational success of PMO therapeutic programs

Phosphorodiamidate morpholino oligomers occupy a compelling niche within the broader RNA-targeted therapeutic landscape, offering a blend of chemical stability, sequence specificity, and clinical applicability across genetic disorders, infectious diseases, and oncology. Scientific progress in conjugation chemistries and formulation science has materially expanded the modalities through which PMOs can be delivered, thereby broadening the therapeutic contexts where they can provide meaningful benefit. At the same time, evolving regulatory clarity and maturation of clinical endpoints underpin more reliable development pathways.

Commercial and operational pressures-most notably supply chain disruptions and tariff-driven cost dynamics-pose practical challenges but also create incentives for strategic supply chain redesign, increased regional manufacturing capacity, and closer alignment between clinical design and production planning. Organizations that integrate delivery optimization, manufacturing readiness, and proactive regulatory engagement will be best positioned to translate PMO science into durable clinical solutions. Continued investment in conjugation innovation, quality systems, and cross-functional execution will determine which programs move from experimental promise to clinical and patient impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Phosphorodiamidate Morpholino Oligomers Market, by Application

  • 8.1. Genetic Disorders
    • 8.1.1. Dmd
    • 8.1.2. Sma
  • 8.2. Infectious Diseases
    • 8.2.1. Bacterial Infections
    • 8.2.2. Viral Infections
  • 8.3. Oncology
    • 8.3.1. Breast Cancer
    • 8.3.2. Lung Cancer

9. Phosphorodiamidate Morpholino Oligomers Market, by Delivery Modality

  • 9.1. Lipid Conjugated
    • 9.1.1. Cholesterol
    • 9.1.2. Docosanyl
  • 9.2. Peptide Conjugated
    • 9.2.1. Penetratin
    • 9.2.2. Tat
  • 9.3. Unconjugated

10. Phosphorodiamidate Morpholino Oligomers Market, by End User

  • 10.1. Contract Research Organizations
  • 10.2. Hospitals And Clinics
  • 10.3. Pharmaceuticals And Biotech Companies
  • 10.4. Research Institutes

11. Phosphorodiamidate Morpholino Oligomers Market, by Formulation

  • 11.1. Liquid
  • 11.2. Lyophilized Powder

12. Phosphorodiamidate Morpholino Oligomers Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Phosphorodiamidate Morpholino Oligomers Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Phosphorodiamidate Morpholino Oligomers Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Phosphorodiamidate Morpholino Oligomers Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Phosphorodiamidate Morpholino Oligomers Market

17. China Phosphorodiamidate Morpholino Oligomers Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Aurigene Pharmaceutical Services Pvt. Ltd.
  • 18.6. Aurobindo Pharma Ltd.
  • 18.7. Avidity Biosciences, Inc.
  • 18.8. BioMarin Pharmaceutical Inc.
  • 18.9. Biosynth AG
  • 18.10. BOC Sciences, Inc.
  • 18.11. Creative Biogene Corporation
  • 18.12. Dr. Reddy's Laboratories Ltd.
  • 18.13. Dyne Therapeutics, Inc.
  • 18.14. Eurofins Genomics, LLC
  • 18.15. Gene Link, Inc.
  • 18.16. Gene Tools, LLC
  • 18.17. GenElixir, Inc.
  • 18.18. Inciton, Inc.
  • 18.19. IntegrateRNA
  • 18.20. Nippon Shinyaku Co., Ltd.
  • 18.21. NS Pharma, Inc.
  • 18.22. Sarepta Therapeutics, Inc.
  • 18.23. Sun Pharmaceutical Industries Ltd.
  • 18.24. Valence Labs, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DELIVERY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DMD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DMD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DMD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY SMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY SMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY SMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DELIVERY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LIPID CONJUGATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LIPID CONJUGATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LIPID CONJUGATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LIPID CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY CHOLESTEROL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY CHOLESTEROL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY CHOLESTEROL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DOCOSANYL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DOCOSANYL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DOCOSANYL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY PEPTIDE CONJUGATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY PEPTIDE CONJUGATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY PEPTIDE CONJUGATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY PEPTIDE CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY PENETRATIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY PENETRATIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY PENETRATIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY TAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY TAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY TAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY UNCONJUGATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY UNCONJUGATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY UNCONJUGATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY PHARMACEUTICALS AND BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY PHARMACEUTICALS AND BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY PHARMACEUTICALS AND BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DELIVERY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LIPID CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY PEPTIDE CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DELIVERY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LIPID CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY PEPTIDE CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DELIVERY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LIPID CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY PEPTIDE CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DELIVERY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LIPID CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY PEPTIDE CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DELIVERY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LIPID CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY PEPTIDE CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DELIVERY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LIPID CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY PEPTIDE CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DELIVERY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LIPID CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY PEPTIDE CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DELIVERY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LIPID CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY PEPTIDE CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DELIVERY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LIPID CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY PEPTIDE CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. GCC PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GCC PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. GCC PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 188. GCC PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 189. GCC PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. GCC PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DELIVERY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 191. GCC PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LIPID CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 192. GCC PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY PEPTIDE CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 193. GCC PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. GCC PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 195. GCC PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DELIVERY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LIPID CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY PEPTIDE CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DELIVERY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LIPID CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY PEPTIDE CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. G7 PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. G7 PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. G7 PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 221. G7 PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 222. G7 PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. G7 PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DELIVERY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LIPID CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 225. G7 PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY PEPTIDE CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 226. G7 PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. G7 PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 228. G7 PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. NATO PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. NATO PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. NATO PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 232. NATO PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 233. NATO PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. NATO PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DELIVERY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 235. NATO PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LIPID CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 236. NATO PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY PEPTIDE CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 237. NATO PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. NATO PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 239. NATO PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DELIVERY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LIPID CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY PEPTIDE CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DELIVERY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY LIPID CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY PEPTIDE CONJUGATED, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)